|
| Press Releases |
|
 |
|
| Tuesday, May 19, 2020 |
|
|
中国生物制药与康方生物共同开发派安普利单抗联合安罗替尼一线治疗晚期肝癌的临床试验数据获ASCO年会接受呈列 |
| 中国领先的创新研发驱动型医药集团 — 中国生物制药有限公司（股份代号：1177）宣布，与康方生物科技（开曼）有限公司（「康方生物」；股份代号：9926），共同开发及商业化的派安普利单抗（AK105，PD-1单抗）联合安罗替尼一线治疗晚期肝细胞癌的临床疗效和安全性二期研究数据摘要，获即将召开的2020年美国临床肿瘤学会（ASCO）年会接受以海报形式呈列。 more info >> |
|
|
中國生物製藥與康方生物共同開發派安普利單抗聯合安羅替尼一線治療晚期肝癌的臨床試驗數據獲ASCO年會接受呈列 |
| 中國領先的創新研發驅動型醫藥集團 — 中國生物製藥有限公司（股份代號：1177）宣佈，與康方生物科技（開曼）有限公司（「康方生物」；股份代號：9926），共同開發及商業化的派安普利單抗（AK105，PD-1單抗）聯合安羅替尼一線治療晚期肝細胞癌的臨床療效和安全性二期研究數據摘要，獲即將召開的2020年美國臨床腫瘤學會（ASCO）年會接受以海報形式呈列。 more info >> |
|
|
Results from Clinical Trials of Penpulimab in Combination with Anlotinib for 1L HCC Co-developed by Sino Biopharmaceutical and Akeso Accepted for Presentation at ASCO Annual Meeting |
| Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the abstracts on phase II study on clinical efficacy and safety of Penpulimab more info >> |
|
| Monday, March 30, 2020 |
|
|
中国生物制药公布2019年年度业绩 |
| 中国领先的创新研发驱动型医药集团—中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2019年12月31日止年度（「年度」）之财务业绩。 more info >> |
|
|
中國生物製藥公佈2019年年度業績 |
| 中國領先的創新研發驅動型醫藥集團—中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈截至2019年12月31日止年度（「年度」）之財務業績。 more info >> |
|
|
Sino Biopharm Announces 2019 Annual Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX: 1177), a leading, innovative research and development driven pharmaceutical conglomerate in the PRC, has announced its financial results for the year ended 31 December 2019 ("the year"). more info >> |
|
| Tuesday, January 21, 2020 |
|
|
Asia-Pacific has Record Year for Clinical Trials says Novotech CRO |
| Novotech CRO the largest biotech CRO in the Asia-Pacific said the region has had a record year for number of studies, experienced world-class sites and investigators, and patient enrolment. more info >> |
|
| Tuesday, November 26, 2019 |
|
|
中国生物制药公布2019年第三季度业绩 |
| 中国领先的创新驱动型医药集团—中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2019年9月30日止九个月（「回顾期」）之未经审核财务业绩。 more info >> |
|
|
中國生物製藥公佈2019年第三季度業績 |
| 中國領先的創新驅動型醫藥集團—中國生物製藥有限公司（「中國生物製藥」或「公司」，連同附屬公司統稱「集團」）（股票編號：1177）公佈截至2019年9月30日止九個月（「回顧期」）之未經審核財務業績。 more info >> |
|
|
Sino Biopharmaceutical Announces 2019 Third Quarterly Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited third quarterly results for the nine months ended 30 September 2019 ("the review period"). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
三菱重工、西豪州パースに脱炭素事業の営業拠点を設立
Apr 7, 2025 14:00: JST
|
|
|
科技創新價值凸顯 優然牧業2024年盈利提升 現金EBITDA同比增38.3%至53.25億元
Apr 7, 2025 13:54 HKT/SGT
|
|
|
陽光保險：業績穩增彰顯發展韌性 香港資管開業再啟新程
Apr 7, 2025 13:08 HKT/SGT
|
|
|
通通AI社交集團公佈2024年度業績
Apr 7, 2025 13:06 HKT/SGT
|
|
|
洲際航天科技業績期聚焦：百星展覽展示AI賦能衛星製造的未來
Apr 7, 2025 13:03 HKT/SGT
|
|
|
海通恒信：深耕金融“五篇大文章” 2024年業務布局持續優化
Apr 7, 2025 13:01 HKT/SGT
|
|
|
又又又派錢了，很賺錢嗎？
Apr 7, 2025 12:58 HKT/SGT
|
|
|
BCQ Achieves Dual Growth in 2024 Revenue and Net Profit Attributable to Shareholders
Apr 7, 2025 12:24 HKT/SGT
|
|
|
Katalon Study Reveals 20% of AI Testers Fear Job Loss
Apr 7, 2025 10:03 HKT/SGT
|
|
|
Forexiro Makes Its Debut at Cyprus Trading Event, Offering Structured Gold Trading on H4
Apr 7, 2025 10:00: JST
|
|
|
Nghiên cứu của Katalon tiết lộ 20% người kiểm tra AI sợ mất việc
Apr 7, 2025 09:34 HKT/SGT
|
|
|
Forexiro Makes Its Debut at Cyprus Trading Event, Offering Structured Gold Trading on H4
Apr 7, 2025 09:00 HKT/SGT
|
|
|
Integration of ION Mobility's assets and IP, set to accelerate TVS Motor's EV footprint in South East Asian markets
Apr 7, 2025 08:30 HKT/SGT
|
|
|
EdgePoint Towers Appoints Ravin Vickneswaran as Chief Operating Officer
Apr 7, 2025 03:06 HKT/SGT
|
|
|
Fosun's Core Businesses Stay Firm Despite One-off Non-cash Loss
Apr 6, 2025 20:30 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
